GSK disclosed detailed Phase 3 results for bepirovirsen, a chronic hepatitis B therapy it licensed from Ionis Pharmaceuticals, with regulatory reviews underway in four markets including the U.S. The company reported outcomes across two late-stage trials, positioning the program for potential regulatory progress as it moves through review timelines. The disclosures underscore how Ionis-origin RNA-targeting platforms are continuing to translate into late-stage efficacy datasets. For investors and partners, the key near-term focus is whether the totality of clinical benefit and safety supports label expansion decisions across the involved jurisdictions. With hepatitis B remaining a major unmet need for functional cure strategies, bepirovirsen’s next milestones are tied directly to ongoing regulatory assessments and any follow-on analyses requested during review.